Cdmo Services
Skip to main content

Explore about our broad range of CDMO Services and Products

Secondary Opportunity for KD Biopharma's Alfa®

Patients with Ulcerative Colitis (UC) often have a persistent inflammation at the mucosal level indicating an unstable disease status, which likely provokes new flare ups of the disease.

Alfa® can reduce this inflammation after 4-8 weeks of treatment!

Alfa® has shown to be very effective in the control of growth and number of sporadic polyps - a further secondary opportunity of significant market size.